Discover
SRPT
Sarepta Therapeutics, Inc.
18.20
2 x 13.17
2 x 22.51
bid
ask
+
0.23
1.28%
2 @ 04:00 PM
18.21 +0.01 (0.05%)
| Ytd | -15.43% | |
| 1y | 2.77% |
17.45
day range
18.41
10.42
52 week range
25.32
| Open | 18.23 | Prev Close | 17.97 | Low | 17.45 | High | 18.41 | Mkt Cap | 1.92B |
| Vol | 3.36M | Avg Vol | 3.17M | EPS | 0.35 | P/E | 52.00 | Forward P/E | 6.68 |
| Beta | 0.20 | Short Ratio | 8.99 | Inst. Own | 99.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 18.09 | 200-d Avg | 19.69 | 1yr Est | 22.00 |
SRPT News
businesswire.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
benzinga.com
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:
benzinga.com
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a
gurufocus.com
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare disease
benzinga.com
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne M
– Accepted for review with target action date of February 28, 2027Sarepta Therapeutics, Inc. (NASDAQ
businesswire.com
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
benzinga.com
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today
U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps lea